CAL
GPCR icon

Capital Analysts LLC’s Structure Therapeutics GPCR Stock Holding History

Capital Analysts LLC’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Hold
18
– – ﹤0.01% 1503
2026
Q1 		$1K Hold
18
– – ﹤0.01% 1497
2025
Q4 		$1K Hold
18
– – ﹤0.01% 1446
2025
Q3 		$1K Buy
+18
New +$359 ﹤0.01% 1405
2025
Q1 		– Sell
-18
Closed – – 1395
2024
Q4 		$0 Hold
18
– – ﹤0.01% 1328
2024
Q3 		$1K Hold
18
– – ﹤0.01% 1264
2024
Q2 		$1K Buy
+18
New +$739 ﹤0.01% 1149

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Capital Analysts LLC's GPCR Position: Q2 2026 in Review

Capital Analysts LLC held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 18 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

Capital Analysts LLC first reported a position in GPCR in Q2 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Capital Analysts LLC held 18 shares of Structure Therapeutics worth $1K as of Q2 2026.
  • Capital Analysts LLC left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1503 holding.
  • Capital Analysts LLC first reported a position in Structure Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.